Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study

Autor: Yasuo Takahashi, Yoichi Yada, Satoshi Asai, Yayoi Nishida, Norio Susa, Tomohiro Nakayama
Rok vydání: 2015
Předmět:
Male
Dihydropyridines
Physiology
Azelnidipine
Tetrazoles
030204 cardiovascular system & hematology
Pharmacology
Blood Urea Nitrogen
Cohort Studies
chemistry.chemical_compound
0302 clinical medicine
030212 general & internal medicine
Olmesartan Medoxomil
Alanine Transaminase
General Medicine
Middle Aged
Biphenyl compound
Drug Combinations
Creatinine
Hypertension
Female
Olmesartan
Azetidinecarboxylic Acid
medicine.drug
Glomerular Filtration Rate
medicine.medical_specialty
Fixed-dose combination
Urology
Renal function
03 medical and health sciences
Internal Medicine
medicine
Humans
Amlodipine
Aspartate Aminotransferases
Propensity Score
Antihypertensive Agents
Aged
Retrospective Studies
business.industry
Biphenyl Compounds
Sodium
Uric Acid
Candesartan
chemistry
Potassium
Benzimidazoles
business
Zdroj: Clinical and experimental hypertension (New York, N.Y. : 1993). 38(2)
ISSN: 1525-6006
Popis: We conducted a retrospective cohort study to evaluate and compare the long-term effects of two single-pill fixed-dose combinations (FDCs), candesartan/amlodipine and olmesartan/azelnidipine, on laboratory parameters in patients in routine clinical practice. We identified an equal number of new users (n = 182) of a candesartan/amlodipine (8/5 mg/day) FDC tablet (CAN/AML users) and a propensity-score matched cohort (n = 182) receiving an olmesartan/azelnidipine (20/16 mg/day) FDC tablet (OLM/AZ users). Generalized estimating equations were used to estimate and compare the effects of the drugs on serum levels of creatinine, estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), uric acid, sodium, potassium, aspartate aminotransferase, and alanine aminotransferase levels up to 12 months after the start of study drug administration. There was a significant increase of serum creatinine level and a significant decrease of eGFR from the baseline period to during the exposure period in both CAN/AML and OLM/AZ users, and a significant increase of BUN level in CAN/AML users. However, there were no significant differences in the mean changes of laboratory parameters between CAN/AML and OLM/AZ users. Our findings suggested that the effects of CAN/AML and OLM/AZ on laboratory parameters, including an unfavorable effect on renal function, were similar at least during 1 year of administration.
Databáze: OpenAIRE
Externí odkaz: